A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant
granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous
infusion (CIV) in patients with leukopenia in association with AIDS virus infection. In
addition, single dose and steady state pharmacokinetics will also be determined.